Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
48.78
USD
|
-2.62%
|
|
-10.56%
|
+118.94%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,105
|
883.5
|
112.1
|
190.9
|
834.5
|
-
|
-
|
Enterprise Value (EV)
1 |
2,105
|
883.5
|
112.1
|
109.6
|
691.7
|
771.4
|
834.5
|
P/E ratio
|
-29.9
x
|
-5
x
|
-0.51
x
|
-1.19
x
|
-5.51
x
|
-5.07
x
|
-7.34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
78
x
|
384
x
|
582
x
|
12.1
x
|
EV / Revenue
|
-
|
-
|
-
|
44.8
x
|
319
x
|
538
x
|
12.1
x
|
EV / EBITDA
|
-34
x
|
-5.29
x
|
-0.52
x
|
-0.87
x
|
-6.17
x
|
-5.13
x
|
-4.65
x
|
EV / FCF
|
-40
x
|
-7.03
x
|
-
|
-0.99
x
|
-6.35
x
|
-5.99
x
|
-13.7
x
|
FCF Yield
|
-2.5%
|
-14.2%
|
-
|
-101%
|
-15.7%
|
-16.7%
|
-7.31%
|
Price to Book
|
-
|
-
|
-
|
2.81
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,550
|
2,990
|
3,141
|
8,570
|
17,108
|
-
|
-
|
Reference price
2 |
825.3
|
295.5
|
35.70
|
22.28
|
48.78
|
48.78
|
48.78
|
Announcement Date
|
3/17/21
|
2/28/22
|
2/7/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
2.447
|
2.171
|
1.434
|
69.13
|
EBITDA
1 |
-61.92
|
-167.2
|
-214.6
|
-125.9
|
-112.1
|
-150.2
|
-179.6
|
EBIT
1 |
-61.97
|
-167.3
|
-215
|
-126.4
|
-125.4
|
-148.6
|
-106
|
Operating Margin
|
-
|
-
|
-
|
-5,164.41%
|
-5,775.12%
|
-10,366.67%
|
-153.27%
|
Earnings before Tax (EBT)
1 |
-61.83
|
-167.1
|
-214
|
-123.3
|
-123.8
|
-153.6
|
-128
|
Net income
1 |
-70.32
|
-167.1
|
-214
|
-123.3
|
-123.8
|
-153.6
|
-128
|
Net margin
|
-
|
-
|
-
|
-5,037.88%
|
-5,699.35%
|
-10,713.48%
|
-185.19%
|
EPS
2 |
-27.60
|
-59.10
|
-69.60
|
-18.69
|
-8.849
|
-9.630
|
-6.642
|
Free Cash Flow
1 |
-52.62
|
-125.6
|
-
|
-111.2
|
-108.9
|
-128.9
|
-61
|
FCF margin
|
-
|
-
|
-
|
-4,543.77%
|
-5,016.44%
|
-8,989.45%
|
-88.24%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
2/28/22
|
2/7/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.683
|
0.781
|
0.468
|
0.515
|
1.758
|
0.0917
|
0.0917
|
0.0917
|
0.1
|
EBITDA
1 |
-44.73
|
-58.56
|
-68.76
|
-60.28
|
-44.19
|
-41.35
|
-37.98
|
-34.85
|
-25.41
|
-27.7
|
-23.14
|
-29.02
|
-29.65
|
-30.29
|
-
|
EBIT
1 |
-44.77
|
-58.66
|
-68.85
|
-60.39
|
-44.29
|
-41.45
|
-38.09
|
-34.96
|
-25.52
|
-27.81
|
-27.84
|
-30.9
|
-32.4
|
-33.07
|
-36.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,577.01%
|
-4,476.31%
|
-5,452.14%
|
-5,399.22%
|
-1,583.35%
|
-33,704.78%
|
-35,345.99%
|
-36,078.32%
|
-36,695.5%
|
Earnings before Tax (EBT)
1 |
-44.7
|
-58.59
|
-68.72
|
-60.19
|
-43.94
|
-41.17
|
-37.46
|
-34.31
|
-24.63
|
-26.88
|
-27.52
|
-30.58
|
-32.08
|
-32.75
|
-36.2
|
Net income
1 |
-44.7
|
-58.58
|
-68.72
|
-60.19
|
-43.94
|
-41.17
|
-37.46
|
-34.31
|
-24.63
|
-26.88
|
-27.52
|
-30.58
|
-32.08
|
-32.75
|
-36.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,483.89%
|
-4,393.34%
|
-5,263.25%
|
-5,219.03%
|
-1,565.07%
|
-33,354.24%
|
-34,995.45%
|
-35,727.8%
|
-36,195.5%
|
EPS
2 |
-15.00
|
-19.50
|
-22.65
|
-19.80
|
-14.40
|
-13.05
|
-10.65
|
-7.350
|
-2.700
|
-2.970
|
-2.092
|
-2.203
|
-2.295
|
-2.298
|
-2.645
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/28/22
|
5/9/22
|
8/8/22
|
11/9/22
|
2/7/23
|
5/11/23
|
8/9/23
|
11/7/23
|
3/5/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
81.3
|
143
|
63.1
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-52.6
|
-126
|
-
|
-111
|
-109
|
-129
|
-61
|
ROE (net income / shareholders' equity)
|
-
|
-62.1%
|
-131%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
7.920
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-44.00
|
-60.20
|
-
|
-
|
-
|
-
|
Capex
|
-
|
1.05
|
-
|
0.05
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
2.04%
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
2/28/22
|
2/7/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
48.78
USD Average target price
135
USD Spread / Average Target +176.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +118.94% | 835M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|